What's in Conrad Arnfinn Bjørshol's pipeline?

Conrad Arnfinn Bjørshol has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Conrad Arnfinn Bjørshol's portfolio?

Top competitors by shared drug class: Aga Khan University, Bent Gymoese Jorgensen, Bnai Zion Medical Center, Corporacion Parc Tauli, Hamad Medical Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/conrad-arnfinn-bj-rshol.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Conrad Arnfinn Bjørshol — Portfolio Competitive Intelligence Brief

Conrad Arnfinn Bjørshol pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)	Anesthesia and Pain Management
Bupivacaine-fentanyl-morphine elective group	Bupivacaine-fentanyl-morphine elective group	marketed	Combination analgesic (local anesthetic + opioids)	Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (fentanyl, morphine)	Anesthesia/Pain Management
Bupivacaine-fentanyl emergency group	Bupivacaine-fentanyl emergency group	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)	Anesthesia, Emergency Medicine, Pain Management

Therapeutic area mix

Anesthesia and Pain Management · 1
Anesthesia, Emergency Medicine, Pain Management · 1
Anesthesia/Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aga Khan University · 1 shared drug class
Bent Gymoese Jorgensen · 1 shared drug class
Bnai Zion Medical Center · 1 shared drug class
Corporacion Parc Tauli · 1 shared drug class
Hamad Medical Corporation · 1 shared drug class
National Institute for Tuberculosis and Lung Diseases, Poland · 1 shared drug class
University of Debrecen · 1 shared drug class
University of Saskatchewan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Conrad Arnfinn Bjørshol:

Cite this brief

Drug Landscape (2026). Conrad Arnfinn Bjørshol — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/conrad-arnfinn-bj-rshol. Accessed 2026-05-16.